Lysyl oxidase G473A polymorphism is associated with increased risk of ovarian cancer

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 915-919

  Wu, Jie ^a   Cai, Chen ^b   Tong, Danian ^c   Hou, Hongchun ^a  

^a JINAN MATERNITY AND CHILD CARE HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LYSINE 6 OXIDASE;

ADULT; ALLELE; ARTICLE; CANCER RECURRENCE; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION; PRIMARY TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ALLELES; BASE SEQUENCE; CHINA; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN-LYSINE 6-OXIDASE; RISK FACTORS;

EID: 84865699119     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0374     Document Type: Article

References (19)

1. Allen M, Jones JL (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223:162-176.
2. Csiszar K (2001) Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucl Acid Res Mol Biol 70:1-32.
3. Fasching PA, Gayther S, Pearce L, et al. (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 3:171-181.
4. Gayther SA, Pharoah PD (2010) The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 20:231-238.
5. Guidozzi F (1996) Screening for ovarian cancer. Obstetric Gynecol Surv 51:696-701.
6. Henmi H, Endo T, Nagasawa K, et al. (2001) Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biol Reprod 64:157-162.
7. Jeay S, Pianetti S, Kagan HM, et al. (2003) Lysyl oxidase inhibits Ras-mediated transformation by preventing activation of NFκB. Mol Cell Biol 23:2251-2263.
8. Jemal A, Siegel R, Xu J, et al. (2010) Cancer Statistics, 2010. CA Cancer J Clin 60:277-300.
9. Lucero HA, Kagan HM (2006) Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63:2304-2316.
10. Min C, Yu Z, Kirsch KH, et al. (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res 69:6685-6693.
11. Min C, Zhao Y, Romagnoli M, et al. (2010) Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubcininduced apoptosis. J Cell Biochem 111:1160-1168.
12. Papachroni KK, Piperi C, Levidou G, et al. (2010) Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J Cell Mol Med 14:2460-2469.
13. Parkin MD, Bray F, Pisani P (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55:74-108.
14. Payne SL, Hendrix MJ, Kirschmann DA (2007) Paradoxical roles for lysyl oxidases in cancer-A prospect. J Cell Biochem 101:1338-1354.
15. Ren J, Wu X, He W, et al. (2011) Lysyl oxidase 473 g > a polymorphism and breast cancer susceptibility in Chinese Han population. DNA Cell Biol 30:111-116.
16. Russo A, Calo V, Bruno L, et al. (2009) Hereditary ovarian cancer. Crit Rev Oncol Hematol 69:28-44.
17. Siddikuzzaman Grace VM, Guruvayoorappan C (2011) Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology 19:117-129.
18. Uzel MI, Scott IC, Babakhanlou-Chase H, et al. (2001) Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem 276:22537-22543.
19. Wu M, Min C, Wang X, et al. (2007) Repression of BCL2 by the tumour suppressor activity of the lysl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 67:6278-6285.